Teva buys into genomics to bolster its in-house R&D

Israeli pharma giant Teva Pharmaceutical ($TEVA) is investing in Cambridge, MA's Immuneering, taking up a stake in the genomics upstart and tapping its expertise to help guide internal drug development. Teva has acquired a 51% share of its partner, the companies said, at the same time agreeing to collaborate on personalized treatments for CNS ailments. Teva plans to use Immuneering's proprietary analytics platform to hone its R&D in the field, relying on its partner to help it make decisions in early development and match the right patients to their ideal therapies, the company said. More

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.